Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
ABSTRACT: SEQUENCING AND GENOMICS SHARED RESOURCE
Sequencing and Genomics (SEQ) provides an integrated platform of technology, expertise, education, and
infrastructure to create an accessible environment for LCCC researchers to undertake cutting-edge genomics
projects. The Core specializes in six major technologies: Next Generation short-read sequencing (Illumina),
long-read sequencing and genomic mapping (Oxford Nanopore Technologies, BioNano Inc.), NanoString
digital RNA quantification, Affymetrix microarrays, Illumina bead array genotyping, and RNAi screening for
functional validation. Through reciprocity with North Carolina State University, the SR also has access to the
Pacific Biosciences Sequel system. These are complemented by LCCC investments in computational
infrastructure and analysis. Over the past five years, LCCC has integrated two new units in partnership with
TPF and CPDM to compliment SEQ, specifically to facilitate translational cancer genomics to seamlessly
support the coordination, project management, and tracking necessary to perform genomics studies on patient
samples from protocol-driven trials. In addition the Translational Genomics Laboratory (TGL) focuses solely on
cancer sample preparation for downstream sequencing, NanoString analysis, or other molecular testing. This
laboratory uses automated instrumentation and stable protocols optimized for limited input and degraded
cancer specimens collected from clinical trials and translational studies. TGL initiates a pathway for clinical
genomics projects through SEQ and subsequent analysis by the bioinformatics SR (BIOIN).
SEQ SR requests $195,591, 3% of the total fiscal year 2019 budget. LCCC faculty were 43% of fiscal year
2020 users. During the past five years SEQ supported the LCCC investigators involved in TCGA. This project
oversaw the molecular characterization of over 20,000 primary tumor and matched normal samples across 33
cancer types. Within the next year, SEQ will acquire an ONT PromethION 24 system, which uses a high-
capacity, long-read sequencing technology capable of high production whole genome sequencing and
transcriptomics. This technology allows for efficient resequencing of whole genomes including repetitive
elements, structural variation, and other problematic regions of the genome. ONT sequencing provides
reproducible detection of small, medium, and large size structural variations, and in the near future the
detection of 5mC.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Basic ScienceBioinformaticsBiological AssayBiological SciencesBudgetsCancer Center Support GrantCancer Research ProjectCell PhysiologyCenter for Translational Science ActivitiesClinicalClinical PathwaysClinical TrialsCollaborationsComputer AnalysisConsultationsDNA ResequencingDataDetectionEducationEnvironmentEquipmentFacultyFutureGenerationsGenomeGenomicsGenomics Shared ResourceGenotypeGleanHeritabilityInfrastructureInstitutionIntakeInvestmentsKnowledgeLaboratoriesMalignant Breast NeoplasmMalignant NeoplasmsMapsMolecularMolecular EpidemiologyMolecular GeneticsNational Clinical Trials NetworkNorth CarolinaPathologistPatient CarePatientsPopulation StudyPrecision Medicine InitiativePreparationPrimary NeoplasmProcessProductionProtocols documentationPublicationsRNARNA interference screenRecordsRepetitive SequenceReproducibilityResearchResearch PersonnelSamplingServicesSourceSpecimenSystemTechnical ExpertiseTechnologyTennesseeTestingThe Cancer Genome AtlasUniversitiesValidationVariantcancer geneticscancer genomicscancer predispositioncancer typeclinical translationcomputer infrastructuredata sharingdesigndigitalepidemiology studyexperiencegenome sequencinginstrumentationmembernanoporenanostringnext generationpeerpublic databasetechnology platformtranscriptometranscriptome sequencingtranscriptomicstranslational cancer researchtranslational genomicstranslational studytreatment armtumorwhole genome
No Sub Projects information available for 5P30CA016086-49 6914
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA016086-49 6914
Patents
No Patents information available for 5P30CA016086-49 6914
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA016086-49 6914
Clinical Studies
No Clinical Studies information available for 5P30CA016086-49 6914
News and More
Related News Releases
No news release information available for 5P30CA016086-49 6914
History
No Historical information available for 5P30CA016086-49 6914
Similar Projects
No Similar Projects information available for 5P30CA016086-49 6914